Pneumococcal

Among adult patients who have reported a case of invasive pneumococcal disease, researchers address the association of risk factors and recurrent disease.

A new surveillance study shows pneumococcal vaccine shifts cut key antibiotic resistance for invasive pneumococcal disease.

Researchers assess the impact of various pneumococcal conjugate vaccines since the introduction of immunization programming.

Machine learning can uncover immune responses to conserved pneumococcal protein antigens.

The pneumococcal vaccine is approved for protection against 21 serotypes in adults over 18 and children between 2 and 17 at high risk of disease.

With continued reports of gradually waning efficacy among pneumococcal vaccines, researchers look toward vaccine effectiveness among patients aged 18 to 64 years.

Alongside malnutrition instances and measles cases, researchers review pneumonia disease burden and immune vulnerability across high-risk pediatric groups.

As pneumococcal disease continues to rise since the COVID-19 pandemic, researchers looked at the need to escalate the management of serotype surveillance and vaccine coverage.

Exploring both the PCV20 and PCV21 pneumococcal vaccines, researchers compare the differences in immune effects between patients at 50 and 65 years old.

In a meta-analysis conducted between 2013 and 2023, researchers explore the overall impact of interventions geared toward boosting pneumococcal vaccination rates.

Across rural US community pharmacies, researchers explore the common barriers and facilitators to pneumococcal vaccine uptake.

Exploring pneumococcal vaccination rates among eligible adult patients, researchers conducted a quality improvement initiative at a clinic in Illinois.

A new 25-valent pediatric pneumococcal vaccine enters phase 3 after strong data, aiming for broader coverage and improved serotype 3 protection.

Among both childhood and adult populations, researchers assess the quality of life across a large cohort of patients reporting pneumococcal disease cases.

Preventing pneumococcal disease remains a cornerstone of public health, yet the strategy for protection is increasingly individualized and complex.

Researchers explore invasive pneumococcal disease epidemiology after the introduction of multiple pneumococcal conjugate vaccines.

Exploring data across a variety of income settings, researchers conduct a review of invasive pneumococcal disease carriage, cases, and their associations.

In adult patients at least 50 years old, researchers estimated lifetime costs and health outcomes of the 23-valent pneumococcal polysaccharide vaccine.

Low pneumococcal vaccine rates have potential to significantly impact a variety of at-risk populations, even groups of certain health care workers.

New research shows older adults vaccinate more when confident navigating their health care.

Meta-analysis shows PCV13 followed by PPSV23 boosts pneumococcal immunity in seniors without added adverse effects.

Social determinants of health shape pneumococcal risk, making vaccination especially important for specific populations.

In response to evolving serotypes and vaccine guidance, researchers assess the most effective pneumococcal vaccination strategies across Taiwan.

Researchers aim to update and expand on register-based surveillance of severe acute respiratory infections related to Streptococcus pneumoniae in Denmark.

Investigators of the multicenter cohort aim to determine if the 13-valent pneumococcal conjugate vaccine impacted disease activity over a 24-month period.